Nurix Therapeutics, Inc. (NRIX) financial statements and ratios from SEC XBRL: revenue $0.0B (TTM), net margin -314.9%, revenue growth 2.2% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $83.98M |
| Revenue (TTM) | $0.0B |
| Net Margin | -314.9% |
| Operating Margin (TTM) | -1590.9% |
| Revenue Growth (YoY) | 2.2% |
| EPS Growth (YoY) | 9.3% |
| FCF Growth (YoY) | 43.5% |
| Price / Book | 6.88 |
| Price / Sales | 94.15 |
| FCF Yield | -18.3% |
| Altman Z-Score | 8.65 (safe) |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Sector P/E (Healthcare) | 21.7 |
NRIX overview · NRIX earnings · NRIX KPIs · NRIX documents · NRIX ownership · NRIX peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.